GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Philogen SpA (STU:78Q) » Definitions » Total Long-Term Assets

Philogen SpA (STU:78Q) Total Long-Term Assets : €36.13 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Philogen SpA Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Philogen SpA's Total Long-Term Assets for the quarter that ended in Dec. 2024 was €36.13 Mil.


Philogen SpA Total Long-Term Assets Historical Data

The historical data trend for Philogen SpA's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Philogen SpA Total Long-Term Assets Chart

Philogen SpA Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Assets
17.59 24.27 26.86 30.03 36.13

Philogen SpA Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.86 27.88 30.03 29.45 36.13

Philogen SpA Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.


Philogen SpA Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Philogen SpA's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Philogen SpA Business Description

Traded in Other Exchanges
Address
Piazza La Lizza No. 7, Siena, ITA, 53100
Philogen SpA is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.

Philogen SpA Headlines

No Headlines